Cannabis Prices Keep Falling. New Global Report Says That Was Always Going To Happen

May 21, 2026

A new analysis from Whitney Economics and GCNC argues that cannabis price compression is not a market failure, but a predictable phase of legalization that regulators and operators repeatedly underestimate.

Cannabis prices have been falling for years. In mature U.S. markets, flower prices have collapsed. In Canada, licensed producers destroyed more than 425 million grams of excess inventory in a single year. In Germany, import volumes have grown nearly 45-fold since 2018 and prices have fallen roughly 25% in two and a half years, according to a new report from Whitney Economics and the Global Cannabis Network Collective. The industry has treated each of these episodes as a crisis. A new global analysis argues they were never anything other than inevitable.

The report, “What You Need to Know: Pricing Compression and Its Impact on International Cannabis Markets,” was published this month by GCNC, a membership organization connecting cannabis operators and investors worldwide, in partnership with Whitney Economics, a cannabis economics research and consulting firm. It draws on market data from the U.S., Canada and Germany, operator perspectives from Israel, Mexico and Peru, and a predictive modelling framework the firm adapted from logistics economics to forecast how pricing behaves at each stage of market development.

The core argument is a reframe. Falling prices in cannabis are not a symptom of industry failure: they are, according to the report, a predictable phase of market maturation that regulators and operators consistently underweight when it matters most — at the beginning, before the damage is done.

“Every cannabis market evolves differently, but the pricing patterns are remarkably consistent,” Beau Whitney, founder and chief economist at Whitney Economics, said in the report. “The operators and investors that perform best are typically the ones using data to anticipate where the market is heading, rather than reacting after margins are already under pressure.”

New markets typically launch with constrained supply, elevated prices and investor optimism. But within three to seven years, according to Whitney Economics’ modelling, supply capacity outpaces demand, triggering annual price declines of 10% to 20% before stabilizing closer to production costs. The problem is not that this cycle exists; it is that regulators focus almost exclusively on controlling demand and access while paying little attention to supply, and that operators build business plans against early-stage pricing rather than the trajectory.

The American Market

In the United States, the data is stark. According to Whitney Economics, authorized supply capacity across U.S. legal cannabis markets now equals roughly 600% of legal demand and 225% of total demand, including illicit demand. Only 27.3% of cannabis operators were profitable in 2024, per the firm’s annual Business Conditions Survey, compared to roughly 65% of U.S. small businesses across all sectors.

Per a 2024 Whitney Economics delinquent payments report, the industry was carrying an estimated $3.8 billion in delinquent payments as of 2023. In 2025, according to Whitney Economics and First Citizens Bank’s joint industry report, U.S. legal cannabis revenues fell to between $28.6 billion and $29.6 billion, down from $30.1 billion in 2024, the first contraction in the history of the regulated market. The firm estimated that 24 states saw declining revenues that year.

The Canadian Precedent

Canada offers the most documented cautionary example. When the country legalized adult-use cannabis federally in 2018, licensed producers moved aggressively to build supply capacity, in part anticipating U.S. federal legalization that never arrived. By April 2020, Health Canada reported that producers were holding more than 600,000 kilograms of unsold unpackaged cannabis. In 2021, Health Canada data cited in the report showed that producers destroyed more than 425 million grams of unpackaged dried cannabis, 26% of total production. More than 42 cannabis-related companies filed for insolvency between 2022 and early 2024. Canadian wholesale flower prices fell nearly 50% between January 2021 and December 2025, according to Global Cannabis Exchange data included in the report.

Germany: The Live Case Study

Germany represents the most current case study and, for international investors and exporters, perhaps the most instructive one. The country’s April 2024 Cannabis Act removed cannabis from the narcotics framework and enabled telemedical prescribing and mail-order dispensing, creating a rapid new patient channel. German cannabis imports grew from 4,476 kilograms in 2018 to an estimated 201,094 kilograms in 2025, according to data from the German Federal Institute for Drugs and Medical Devices.

The market now has enough import supply to support between 900,000 and one million consumers, according to the report, in a market estimated to have 700,000 to 900,000 actual patients. The result has been a price decline of approximately 25% in two and a half years, with the lowest pharmacy-level retail prices approaching four euros per gram and wholesale prices near two euros.

“As reimbursement structures and access pathways evolved, the market shifted quickly from scarcity-driven pricing to competitive pricing pressure,” Aleksandra Vujinovic, founder of AV Legal, a boutique law firm specializing in corporate and cannabis matters, said in the report. “That transition impacted supply chains, operational planning, and long-term positioning almost immediately.”

Germany’s trajectory is further complicated by regulatory uncertainty. A proposed government amendment would ban telemedical initial prescriptions and mail-order dispensing of cannabis flower. The bill passed its first parliamentary reading in December 2025. The outcome remains unsettled, but the direction has shifted, and that uncertainty is itself a market condition operators must now price in.

A Pattern That Can Be Modelled

The report argues cannabis pricing follows a logistics curve, or S-curve, rather than a straight line: slow declines early, rapid compression during expansion phases, then eventual stabilization as markets mature and weaker operators exit. By modelling where a given market sits in that arc operators can build compression into their cost structures before the pressure arrives rather than after margins have already moved.

Not all markets are compressing at the same pace. Missouri has maintained relatively stable basket amounts since 2023, a result of controlled licensing that kept supply and demand closer to balance. Switzerland’s pharma-centric medical model, with strict entry standards and supply controls, is cited in the report as a regulatory structure that has preserved pricing stability. The pace and severity of compression are largely a policy choice, and one that most jurisdictions have made poorly by default.

“This report is designed to provide a clearer line of sight into how markets evolve, where pricing pressure is emerging, and what operators should be watching before making expansion decisions,” Jillian Reddish, co-founder of GCNC, said in a statement.

The implications extend beyond the data. As cannabis markets in Europe, Latin America and other emerging regions develop, the pattern documented across North America and Germany offers a roadmap, not of inevitable disaster, but of predictable cycles that reward anticipation and punish assumption. The operators and investors who have fared best are those who understood that early-stage pricing was never the baseline. It was the starting line.

Pricing compression in cannabis does not signal that the industry is broken. It signals that the industry is maturing. The difference, for those who miss it, tends to show up on the balance sheet.

Search

RECENT PRESS RELEASES